Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Plasticell and EMD Millipore Complete Licensing Deal

Published: Tuesday, January 01, 2013
Last Updated: Tuesday, January 01, 2013
Bookmark and Share
Deal to distribute fully defined, xeno-free mesenchymal stem cell differentiation media.

Plasticell has licensed EMD Millipore to distribute a superior, single-application osteogenic medium discovered using the award winning, massively parallel combinatorial screening system, CombiCult®.

The osteogenic medium is serum- and xeno- free, more consistent and more potent than currently available formulations.

Under the terms of the contract, EMD Millipore has secured a license to distribute the medium globally for research purposes with Plasticell retaining full rights over therapeutic applications.

Early adopters of the medium include Organovo, Inc., a leading San Diego biotech company developing tissue bioprinting applications.

Dr. Eric Michael David MD JD, Chief Strategy Officer of Organovo, Inc. commented, “Organovo, Inc considers Plasticell's CombiCult® bone differentiation media to be a significant leap forward in helping to create 3D bone tissue for a multiple variety of research and transplant applications. Brief incubation of 3D tissue constructs generated with Organovo's NovoGen MMX Bioprinter™ in Plasticell's CombiCult® bone differentiation media produces tissue of impressive osteogenic potential, including key bone-specific and mineralization markers. We found we could rapidly fabricate functional, fully human tissue derived from MSCs and the ECM proteins they produce. Plasticell's media enabled a remarkable efficiency in tissue fabrication and maturation, and we look forward to continuing to work with Plasticell's technology to generate additional bioprinted 3D tissues from well-characterized, renewable, quality cell sources such as MSCs.”

The optimized osteogenic medium was developed using CombiCult® to perform a rapid screen of 3,375 combinations of fully defined cell culture media, equivalent to hundreds of thousands of combinations of media components.

“The formulation of this medium in under 3 months from start to finish is a clear demonstration of the capability of the CombiCult® technology to deliver market-leading products in record time,” said Dr Jey Jeyakumar, the Principal Scientist who performed the factor screen and optimized the media formulation.

In contrast to all currently available osteogenic media, Plasticell’s formulation is fully defined (serum-free) and contains no xenogeneic components.

Moreover, mineralization can be detected in less than one week, whereas competing products that contain serum require approximately 21 days to attain similar levels of bone formation.

Plasticell’s unique medium will be available for research purposes from EMD Millipore in Q3 2012 and available now for commercial applications directly from Plasticell.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Plasticell Appoints Dr Aaron T. T. Chuang as Chief Scientific Officer
New appointment further strengthens the company’s expertise in regenerative medicine product development.
Tuesday, June 16, 2015
Plasticell Wins Innovate UK Funding
Funding for £1.6 million cord blood stem cell manufacturing project.
Friday, February 06, 2015
Plasticell Signs Deal with JCR Pharmaceuticals
Collaboration agreement to use CombiCult® stem cell technology in Japan.
Tuesday, February 25, 2014
Additional Family of CombiCult® Patents Granted in USA, Europe, Australia and Singapore
Newly granted patents cover the use of nanomaterial tags.
Tuesday, November 19, 2013
Plasticell and Veritas Announce an Exclusive Distribution Agreement in Japan
Veritas engaged as exclusive distributor for Plasticell’s services and products, including CombiCult®.
Monday, June 18, 2012
Plasticell Announces Grant of Fundamental CombiCult™ Patents in USA and Japan
Patents have now been issued in Europe, USA, Japan, Australia and Singapore.
Tuesday, February 14, 2012
Plasticell Wins Further Funding for Stem Cell Manufacturing Project
Technology Strategy Board will provide a grant of approximately £750k towards a £1.5m project.
Wednesday, December 14, 2011
Plasticell Delivers Differentiation Protocols to Stemnion, Inc.
Plasticell announces successful completion of a collaboration with Stemnion, Inc..
Tuesday, August 09, 2011
Plasticell Spins Out Regenerative Drug Discovery Venture
New demerged business called ‘Progenitor Labs’.
Thursday, April 14, 2011
Plasticell Completes £3.5 Million Financing Round
Capital injection to expand business development and marketing initiatives to increase growing customer base.
Wednesday, February 16, 2011
Plasticell Signs Technology Agreement with Sigma-Aldrich
Collaboration to produce novel turnkey solution for stem cell research.
Monday, November 29, 2010
Plasticell Signs Stem Cell Research Collaboration with UCB
Plasticell will screen UCB’s drug compound libraries using CombiCult™ technology to discover new cell signaling pathways involved in stem cell biology.
Tuesday, November 09, 2010
Plasticell Signs Collaboration with UCB
First in kind deal to partner small molecule drugs for stem cell research.
Monday, November 08, 2010
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!